News - Valeant Pharmaceuticals


Current filters:

Valeant Pharmaceuticals

Popular Filters

1 to 25 of 54 results

Valeant Pharma returns to profit, boosted by B&L acquisition


Canadian drugmaker Valeant Pharmaceuticals International has announces fourth quarter financial results…

Bausch & LombFinancialGenericsValeant Pharmaceuticals

Valeant spending $475 million to boost dermatology portfolio

Valeant spending $475 million to boost dermatology portfolio


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into a definitive agreement…

DermatologicalsMergers & AcquisitionsPharmaceuticalPreCision DermatologyValeant Pharmaceuticals

Patent settlements for Pfizer/Teva and Mylan/Eisai

Patent settlements for Pfizer/Teva and Mylan/Eisai


US pharma behemoth Pfizer says it has settled its long-standing litigation against a US subsidiary of…

Banner PharmacapsEisaiGenericsLegalMen's HealthMylan LaboratoriesNorth AmericaOncologyPatentsPfizerTargretinTeva Pharmaceutical IndustriesValeant PharmaceuticalsViagra

Valeant agrees $142.5 million settlement with Anacor


Anacor Pharmaceuticals says it has entered into a $142,5 million settlement agreement with Canada-based…

Anacor PharmaceuticalsFinancialLegalNorth AmericaPharmaceuticalValeant Pharmaceuticals

Anacor Pharma awarded $100 million damages


Anacor Pharmaceuticals says that the arbitrator appointed to resolve its dispute with Canada-based Valeant…

Anacor PharmaceuticalsLegalNorth AmericaPharmaceuticalValeant Pharmaceuticals

Valeant Pharma beats forecasts, turns in profit


Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) announced second quarter financial…

Bausch & LombFinancialGenericsValeant Pharmaceuticals

Valeant confirms plan to acquire Bausch & Lomb in a $8.7 billion transaction


Following speculation ahead of the extended holiday weekend, acquisitive Canadian drugmaker Valeant Pharmaceuticals…

Bausch & LombMergers & AcquisitionsOphthalmicsPharmaceuticalValeant Pharmaceuticals

Actavis and Valeant report first quarter 2013 results


US generics drug major Actavis (NYSE: ACT) and Canada's Valeant Pharmaceuticals (TSX: VRX) both presented…

ActavisFinancialGenericsValeant Pharmaceuticals

Actavis in OxyContin patent settlement; Valeant takeover bid "on hold"?


US generic major Actavis (NYSE: ACT) has entered into an agreement with privately-held Purdue Pharma…

ActavisGenericsMergers & AcquisitionsNeurologicalNorth AmericaOxyContinPatentsPurdue PharmaValeant Pharmaceuticals

Actavis settles with Valeant to launch generic Ziana and Zyclara in USA


US generics drug major Actavis (NYSE: ACT) has reached settlement agreements with Medicis Pharmaceutical,…

ActavisGenericsMarkets & MarketingNorth AmericaPatentsValeant PharmaceuticalsZiana GelZyclara

Actavis and Valeant to co-promote Zovirax and Cordran Tape


Valeant Pharmaceuticals International (TSX: VRX) entered into an agreement, effective immediately, for…

ActavisAnti-viralsCordran TapeGenericsLicensingMarkets & MarketingMylan LaboratoriesNorth AmericaValeant PharmaceuticalsZovirax Ointment

Merz Pharma enters bidding war for Obagi; Ferro sells pharma unit


German family-owned firm Merz Pharma has written to the board of director of Obagi Medical Products outlining…

Ferro GroupGenericsMergers & AcquisitionsMerz PharmaceuticalsObagi Medical ProductsPfanstiehl LaboratoriesPharmaceuticalValeant Pharmaceuticals

Valeant to acquire Obagi Medical for around $344 million


Canada-based Valeant Pharmaceuticals International (TSX: VRX) is on the acquisition trail again, announcing…

DermatologicalsMergers & AcquisitionsObagi Medical ProductsPharmaceuticalValeant Pharmaceuticals

Valeant Pharma buys US rights to Eisai's Targretin for $65 million upfront


Canada's Valeant Pharmaceuticals International (TSX: VRX) says that it has acquired US rights for Targretin…

EisaiLicensingNorth AmericaOncologyPharmaceuticalTargretinValeant Pharmaceuticals

News briefs from Bayer, AstraZeneca and Valeant/Galderma


German drug major Bayer (BAYN: DE) and partner Regeneron (Nasdaq: REGN) submitted a marketing application…

AstraZenecaBayerEuropeEyleaFaslodexGaldermaLicensingNorth AmericaOncologyOphthalmicsPerlanePharmaceuticalRegulationRestylaneValeant Pharmaceuticals

Valeant may pull out of Russian Natur Produkt acquisition


According to local sources in Russia, acquisitive Canadian drugmaker Valeant Pharmaceuticals (TSX: VRX)…

Mergers & AcquisitionsNatur ProduktPharmaceuticalValeant Pharmaceuticals

Valeant Pharma acquires Visudyne from QLT


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) said yesterday that it…

Mergers & AcquisitionsOphthalmicsPharmaceuticalQLTValeant PharmaceuticalsVisudyne

Valeant on the prowl again, with bid to buy Medicis for about $2.6 billion


In a sixth acquisition so far this year, as well as several takeovers the previous year, Canada's Valeant…

DermatologicalsMedicis PharmaceuticalMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

1 to 25 of 54 results

Company Spotlight



Back to top